VYKAT XR

About Soleno Therapeutics

Soleno Therapeutics is a Redwood City, California-based biopharmaceutical company dedicated to addressing unmet medical needs in rare genetic disorders. The company achieved a major milestone with the FDA approval and commercialization of VYKAT XR for hyperphagia in Prader-Willi syndrome, establishing its first commercial product. With experienced leadership that includes executives who have successfully guided companies through product launches and acquisitions, Soleno is positioned to build on its initial success and expand its rare disease portfolio. The company operates as a public entity (NASDAQ: SLNO) with a market valuation reflecting its commercial-stage status.

Therapeutic Areas